Exchange: NASDAQ·Updated 04:45 PM EST

AGMB News

News
all
press releases
HC Wainwright Has Optimistic Opinion of AGMB FY2026 Earnings
AgomAb Therapeutics NV (NASDAQ:AGMB - Free Report) - Research analysts at HC Wainwright boosted their FY2026 EPS estimates for shares of AgomAb Therapeutics in a research note issued on Monday, November 16th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per s...
MarketBeat
HC Wainwright Has Optimistic Opinion of AGMB FY2026 Earnings
AgomAb Therapeutics NV (NASDAQ:AGMB - Free Report) - Research analysts at HC Wainwright boosted their FY2026 EPS estimates for shares of AgomAb Therapeutics in a research note issued on Monday, November 16th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per s...
MarketBeat
More News
AgomAb Therapeutics (NASDAQ:AGMB) Hits New 52-Week Low - Time to Sell...
MarketBeat
AgomAb Therapeutics' (NASDAQ:AGMB - Get Free Report) quiet period is set to expire on Wednesday, March 18th. AgomAb Therapeutics had issued 12,500,000 shares in its IPO on February 6th. The total...
MarketBeat
Zacks Research raised AgomAb Therapeutics to a "hold" rating in a research report on Wednesday...
MarketBeat
AgomAb Therapeutics (NASDAQ:AGMB) Shares Down 4.5% - What's Next...
MarketBeat
AgomAb Therapeutics (NASDAQ:AGMB) Hits New 52-Week High - Here's What Happened...
MarketBeat
Leerink Partners began coverage on AgomAb Therapeutics in a research note on Tuesday. They set an "outperform" rating and a $36.00 target price on the stock...
MarketBeat
Morgan Stanley began coverage on shares of AgomAb Therapeutics in a report on Tuesday. They set an "overweight" rating and a $28.00 target price for the company...
MarketBeat
JPMorgan Chase & Co. started coverage on shares of AgomAb Therapeutics in a report on Tuesday. They issued an "overweight" rating and a $32.00 target price on the stock...
MarketBeat

Advertisement|Remove ads.